
Osapiens Raises US$ 100M in Series C Funding
Why It Matters
The infusion underscores growing investor appetite for tech solutions that embed sustainability into core operations, positioning osapiens to capture expanding demand for AI‑driven ESG compliance. It also signals confidence in the company’s ability to scale its HUB platform globally.
osapiens Raises US$ 100M in Series C Funding
By FinSMEs · January 14, 2026

osapiens, a Mannheim, Germany‑based provider of enterprise software for sustainable growth, raised US$ 100 million in a Series C funding round.
The round was led by Decarbonization Partners, a joint venture between BlackRock and Temasek, and included existing investors Goldman Sachs Alternatives (lead investor in the US$ 120 million Series B in 2024) and Armira Growth (lead investor in the US$ 27 million Series A in 2023).
The company plans to use the new capital to accelerate product innovation, expand into existing and new international markets, and strengthen its position as a global platform for sustainable growth.
Founded by Alberto Zamora, Stefan Wawrzinek, and Matthias Jungblut, osapiens develops software that enables companies to drive sustainable growth across their entire value chain. Its HUB, a multi‑tenant hyperscaler platform designed for cross‑company collaboration and AI automation, combines more than 25 solutions in two categories:
- Transparency solutions – allow companies to report on financial and non‑financial data, manage supply chains, mitigate a wide range of risks (including cyber, trade, and geopolitical risks), and ensure compliance with product, reporting, and supply‑chain regulations.
osapiens now employs over 550 professionals across Europe and the United States and serves more than 2,400 customers worldwide, including global leaders such as Coca‑Cola North America, Lidl, Carrefour, OTTO, and the Acciona‑Nordex Group.

osapiens founders – Matthias Jungblut, Stefan Wawrzinek, Alberto Zamora (left to right)
FinSMEs – 14/01/2026
Tags: Decarbonization Partners, osapiens
Comments
Want to join the conversation?
Loading comments...